You know, I think probably the biggest one is don’t sit on patients that are not responding well to JAK inhibitors. Unfortunately, you do see that. Like, patients are on maybe ruxolitinib as their first line of therapy, and they’re clearly not optimized on the therapy. They’re on a low dose. Their spleens are still large. They’re still harboring symptom burdens, maybe they’re becoming cytopenic...
You know, I think probably the biggest one is don’t sit on patients that are not responding well to JAK inhibitors. Unfortunately, you do see that. Like, patients are on maybe ruxolitinib as their first line of therapy, and they’re clearly not optimized on the therapy. They’re on a low dose. Their spleens are still large. They’re still harboring symptom burdens, maybe they’re becoming cytopenic. I think often people will wait till sort of the very end to make a treatment switch. And I think it’s very hard to salvage it when the patients are very advanced. So my advice would be if the patient is not optimized, they haven’t had significant spleen response, they still have lingering symptoms, or they’re really developing anemia and thrombocytopenia, to be more on top of that switch. Don’t wait and be reactive. I would say be proactive and think about whether that patient would be better on pacritinib or momelotinib or fedratinib or, you know, I’m always biased, clinical trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.